S&P Futures
3,986.25 +3.25 (+0.08%) Dow Futures
32,481.00 +25.00 (+0.08%) Nasdaq Futures
12,687.25 -1.25 (-0.01%) Russell 2000 Futures
1,766.70 +6.00 (+0.34%) Crude Oil
67.29 -0.35 (-0.52%) Gold
1,985.10 +2.30 (+0.12%)
Ambrx Biopharma Inc. American Depositary Shares (AMAM)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.93 |
| Open | 9.00 |
| Bid | 9.63 x 900 |
| Ask | 9.75 x 800 |
| Day's Range | 8.82 - 9.80 |
| 52 Week Range | 0.38 - 13.07 |
| Volume | |
| Avg. Volume | 4,921,415 |
| Market Cap | 533.351M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 1.70 |
| EPS (TTM) | 5.68 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AMAM
Related Research
- Ambrx Biopharma Inc.Daily – Vickers Top Buyers & Sellers for 09/02/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 months agoArgus Research
- Business Wire
Ambrx Raises $78 Million and Completes its ATM Program
SAN DIEGO, March 13, 2023--Ambrx Biopharma Inc., or Ambrx (NYSE: AMAM), today announced that it has completed net sales of approximately $78 million of American Depositary Shares ("ADSs") pursuant to the Company’s at-the-market ("ATM") program established on Aug 5, 2022, through Cowen and Company LLC ("TD Cowen"), acting as sales agent. The ATM program had an aggregate offering price of up to $80 million in gross proceeds. Through the utilization of the ATM, the Company has raised $78 million in
- Motley Fool
Why Shares of Ambrx Biopharma Fell Tuesday
After getting a bump on Monday for its switch to the Nasdaq Stock Market, there was a bit of a correction.
- Business Wire
Ambrx to Commence Trading on Nasdaq
SAN DIEGO, March 06, 2023--Ambrx Biopharma Inc. (NYSE: AMAM) ("Ambrx" or "the Company") today announced that it will voluntarily transfer its stock exchange listing to the Nasdaq Stock Market from the New York Stock Exchange, effective March 16, 2023 after market close. Ambrx’s American Depositary Shares are expected to begin trading as a Nasdaq-listed security on March 17, 2023. The Company will retain its current ticker symbol "AMAM".
